simeprevir

Known as: HSDB 8227, N-(17-(2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo(13.3.0.04,6)octadec-7-ene-4-carbonyl)(cyclopropyl)sulfonamide, Simeprevir [Chemical/Ingredient] 
An orally bioavailable inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
05010015020132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
UNLABELLED Hepatitis C virus (HCV)-infected patients with cirrhosis are historically a difficult-to-treat population and are at… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Treatment of hepatitis C virus with potent, interferon-free, direct-acting antiviral regimens with no activity against hepatitis… (More)
  • figure 1
Is this relevant?
Highly Cited
2015
Highly Cited
2015
UNLABELLED Treatment with an all-oral interferon-free antiviral regimen using simeprevir and sofosbuvir with or without ribavirin… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Highly Cited
2014
Highly Cited
2014
BACKGROUND Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were the standard of care in patients with… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS Simeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS Simeprevir (TMC435) is an oral NS3/4 protease inhibitor in phase III trials for chronic hepatitis C virus (HCV… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS In a Japanese Phase II study, the hepatitis C virus NS3/4A protease inhibitor simeprevir demonstrated potent… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
UNLABELLED The phase IIb, double-blind, placebo-controlled PILLAR trial investigated the efficacy and safety of two different… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?